Scratching my head over the different reactions to the FGEN and CARA offerings. Not that I'm complaining about the former. Stifel a participant in both. There is a different level of clinical uncertainty, and CARA had a much bigger run prior to the offering, but still . . .
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.